The Role of Lung Ultrasound in the Assessment of Novel Coronavirus Pneumonia.
Zhongheng Zhang,Binbin Ren,Haozhe Fan,Kun Chen,Lin Chen
DOI: https://doi.org/10.1053/j.jvca.2020.04.040
IF: 2.894
2020-01-01
Journal of Cardiothoracic and Vascular Anesthesia
Abstract:A NOVEL coronavirus was discovered in the lower respiratory tract of a group of patients with pneumonia in Wuhan, Hubei province, China, in December 2019.1Zhu N. Zhang D. Wang W. et al.A novel coronavirus from patients with pneumonia in China, 2019.N Engl J Med. 2020; 382: 727-733Crossref PubMed Scopus (18374) Google Scholar The disease caused by this novel coronavirus officially was named coronavirus disease-2019 (COVID-19) by the World Health Organization on February 11, 2020, and it has a highly infectious rate and a high mortality rate. As of April 1, there were 754,948 global infections of COVID-19, with 36,571 deaths (https://www.who.int/diagnostics_laboratory/EUL/en/). Although symptoms for most patients with COVID-19 are mild (common type) and those patients can recover spontaneously without specific treatment, a substantial proportion of patients will develop a severe case. The management of such severe cases is challenging. Early identification, evaluation of disease progress, and timely treatment of patients with COVID-19 are the keys to reducing the mortality of these patients. Lung ultrasound, a rapid, convenient, radiation-free, economical, repeatable, and bedside visual examination technology for lung diseases, plays an essential role in the diagnosis and treatment of critically ill patients. Lung ultrasound has advantages in the differential diagnosis of pulmonary exudative diseases, the evaluation of pleural effusion, the recognition of pneumothorax, the evaluation of dyspnea and acute respiratory failure, the monitoring of treatment, the evaluation of curative effect, and the guidance of treatment, and has formed a consensus of many experts worldwide. Because of the high infectiousness of the novel coronavirus pneumonia, we should make full use of lung ultrasound to guide diagnosis and treatment during the different stages of the disease. •B-line: A linear hyperecho starts from and runs perpendicular to the pleura line and radiates longitudinally to the deep part of the lung field.•Lung point sign: With real-time ultrasound and respiratory movement, the lung point is the boundary point between the existence of a pulmonary slip and the disappearance of a pulmonary slip.•Pulmonary pulsation sign: This sign reflects the insufficient inflation of the lung with movement of the pleura line consistent with that of heart. The existence of this sign can exclude pneumothorax.•Stratospheric sign: When lung slip disappears, the particle-like spot echo under the pleura line is replaced by a series of parallel lines with M-mode ultrasound.•Alveolar interstitial syndrome: This occurs when there are more than 2 consecutive costal spaces in any scanning area with a fusion B-line.•White lung: A dense B-line is found in each scanning area of both lungs. The lung of a COVID-19 patient will demonstrate the formation of serous, fibrinous exudate and hyaline membrane in the alveoli. The epithelial cells of type II alveoli proliferate significantly. The blood vessels of the alveoli septum are congested and edematous, and bleeding and necrosis of the pulmonary tissue also are present. Some alveoli exudates are organized, and pulmonary interstitial fibrosis may occur. Disease onset often starts from the lateral zone of the lung, close to the pleura; therefore, pulmonary ultrasound can more effectively demonstrate the pathologic and dynamic changes of the lung condition. The following lung pathological changes with different ultrasound signs in patients with COVID-19:•Pulmonary consolidation: Solid tissue echo is present after the complete loss of lung tissue gasification, with patchy or "liverlike change" of different sizes, which may be accompanied by "signs of broncho inflation" or "signs of broncho fluid filling."•Pleural effusion: Hypoechoic or nonechoic areas are visible in the pleural cavity, with cordlike separation. When empyema occurs, it should be distinguished from solid lung tissue.•Pneumothorax: This is demonstrated when areas of the pleura line, A-lines, and lung sliding sign disappear without the existence of B-lines. The lung point sign and stratospheric sign may be visible with M-mode. Changes of the lung ultrasound for novel coronavirus pneumonia include a thickened pleural line (Fig 1), B-lines in different degrees (Fig 2, A and B), and fusion B-lines (Fig 3). This can be manifested as focal B-lines and diffuse alveolar interstitial syndrome (Fig 4), according to the different divisions. Fragmentation can be found in subpleural consolidations (Fig 5). Tissue-like (Fig 6) and dynamic bronchiectasis can be seen in a large consolidation of the lung accompanied by bronchiectasis (Fig 7). There are many abnormal examination parts. B-lines are mainly focal in the early and mild stages of novel coronavirus pneumonia. Pulmonary interstitial syndrome and consolidation mainly occur in the progressive stage. Normal A-lines on pulmonary ultrasound can be completely recovered or the pleura line with pulmonary fibrosis accompanied with uneven B-line changes can be seen in the convalescent stage.Fig. 2(A) Separate B-lines. (B) Multiple B-lines.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Fig. 3Fusion B-lines.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Fig. 4Diffuse alveolar interstitial syndrome.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Fig. 5Fragmentation sign.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Fig. 6Tissuelike.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Fig. 7Bronchiectasis in large consolidation of the lung.View Large Image Figure ViewerDownload Hi-res image Download (PPT) We should focus on the presence or absence of an abnormal pleura line (smooth, continuous); B-lines (number and distribution); consolidation (range, bronchiectasis); pleural effusion (nature); and pneumothorax, etc. The sonograms of B-lines, alveolus interstitial syndrome, and white lung reflect the degree of lung water from light to heavy. Sezgin et al. reported that the sensitivity and specificity of pulmonary ultrasound in the diagnosis of pneumonia are 98.0% and 95.8%, respectively,4Sezgin C. Gunalp M. Genc S. et al.Diagnostic value of bedside lung ultrasonography in pneumonia.Ultrasound Med Biol. 2020; 46: 1189-1196Abstract Full Text Full Text PDF PubMed Scopus (15) Google Scholar and the diagnostic rate of pneumothorax can reach 100%.7Lichtenstein D. Meziere G. Biderman P. et al.The "lung point": An ultrasound sign specific to pneumothorax.Intensive Care Med. 2000; 26: 1434-1440Crossref PubMed Scopus (513) Google Scholar The lung ultrasound signs and pathologic signs already have been well-known by clinicians. In addition, the novel coronavirus pneumonia is highly infectious. In order to reduce the transmission, it is better to perform the examination as infrequently as possible. With the limitation of bedside chest x-ray, which exposes medical personnel and patients to high radioactive activity, lung ultrasound is a better choice of bedside diagnostic equipment. With its convenient, noninvasive, repeatable, radiation-free, and rapid results, lung ultrasound has been used widely in the critical care area. Because the pneumonia with the novel coronavirus changes rapidly, combined with the characteristics of the pathology of this pneumonia, lung ultrasound is better suited to provide full and effective assessment of the lung condition, which can result in sufficient guidance for diagnosis and treatment. The advantages of lung ultrasound are summarized in the following. First, with its convenient, noninvasive, repeatable, and nonradioactive characteristics, lung ultrasound can be performed at the bedside, which is beneficial to the examiner and the patient by reducing the probability of transmission of the disease. Second, accurate information can be obtained to help provide a diagnosis on the basis of the ultrasound imaging. Third, if the patient's condition changes, ultrasound can provide a quick examination to determine whether pneumothorax or increasing pleural effusion is present. Bedside puncture can be performed on the basis of the lung ultrasound. Ultrasound also can demonstrate whether there is an increase of lung edema and, combined with the parameters of oxygenation, can direct whether mechanical ventilation and other treatments are needed. Fourth, lung evaluation findings, combined with parameters of oxygenation, hemodynamics, and ventilation, can be used to determine the timing of implementation of extracorporeal membrane oxygenation. Fifth, for critically ill patients who have been treated with mechanical ventilation or extracorporeal membrane oxygenation, we can evaluate the condition of the lungs dynamically, further clarifying the prognosis. Sixth, the evaluation of the inferior vena cava and heart by ultrasound provides great value for the differential diagnosis when the patient's condition changes rapidly. Finally, it is easy to acquire and transmit images of the ultrasound, which are essential for remote diagnosis and treatment. There are also limitations of lung ultrasound. When there are pathologic changes in the deep part of lung field and no pathologic changes of the pleural, its advantages are reduced significantly. However, in order to decrease the probability of transmission, to better perform dynamic diagnosis of the novel coronavirus pneumonia, and to provide better protection of medical workers and patients, lung ultrasound should be used to the fullest. None.